In a SHaRe registry observational cohort of 3,117 genotyped patients with dilated cardiomyopathy, new-onset atrial fibrillation was independently linked to a 1.58-fold higher risk of adverse clinical outcomes. Cases show room to sharpen frontline surveillance: LMNA carriers had the highest AF incidence at 7.6 per 100 patient-years and a cumulative AF prevalence of 56.7%, making early recognition especially high-stakes in the patients you often know best.

Why It Matters To Your Practice

• NPs and PAs are often the first clinicians to catch rhythm changes, symptom drift, or decompensation in DCM—well before a crisis or specialist callback.

• In this cohort, 12.3% had prevalent AF at baseline, and 12.5% of those without AF developed it over a median 4.5 years.

• Only LMNA was independently associated with incident AF versus genotype-negative patients, with a hazard ratio of 5.52.

• Older age, male sex, and prior Heart Failure (CHF) hospitalization also raised incident AF risk.

Clinical Benefits

• Your monitoring, triage, and follow-up can directly influence earlier AF detection in high-risk DCM patients.

• Genotype-aware surveillance may help prioritize who needs closer rhythm review, symptom checks, and faster escalation.

• LMNA-positive patients stand out as a group where your vigilance can be especially impactful.

• Recognizing AF early may support more timely decisions around anticoagulation, rate or rhythm management, and referral.

Managing Risks

• Do not assume AF risk is uniform across DCM subtypes; TTN patients had AF rates comparable to genotype-negative patients, while LMNA risk was much higher.

• Watch for subtle presentations such as palpitations, exertional decline, fatigue, edema, or worsening exercise tolerance.

• Patients with prior Heart Failure (CHF) hospitalization deserve extra attention, given their higher likelihood of incident AF.

• Build low-friction surveillance into routine care: pulse checks, ECG review when symptoms shift, and prompt escalation for suspected arrhythmia.

The Bottom Line

• AF in genotyped DCM is not just common—it is prognostically important.

• Frontline NPs and PAs are not secondary players here; your assessment is often the difference between delayed recognition and timely intervention.

• The study supports genotype-guided AF surveillance, with the strongest signal in LMNA-associated DCM.

• When AF appears, the stakes rise: adverse outcomes increased by 58%.